These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 28493068)

  • 1. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
    Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
    Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MAPT gene is differentially methylated in the progressive supranuclear palsy brain.
    Huin V; Deramecourt V; Caparros-Lefebvre D; Maurage CA; Duyckaerts C; Kovari E; Pasquier F; Buée-Scherrer V; Labreuche J; Behal H; Buée L; Dhaenens CM; Sablonnière B
    Mov Disord; 2016 Dec; 31(12):1883-1890. PubMed ID: 27709663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter.
    Zhukareva V; Joyce S; Schuck T; Van Deerlin V; Hurtig H; Albin R; Gilman S; Chin S; Miller B; Trojanowski JQ; Lee VM
    Ann Neurol; 2006 Sep; 60(3):335-45. PubMed ID: 16823854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [
    Schönecker S; Palleis C; Franzmeier N; Katzdobler S; Ferschmann C; Schuster S; Finze A; Scheifele M; Prix C; Fietzek U; Weidinger E; Nübling G; Vöglein J; Patt M; Barthel H; Sabri O; Danek A; Höglinger GU; Brendel M; Levin J;
    Neuroimage Clin; 2023; 38():103402. PubMed ID: 37087820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
    Rojas JC; Bang J; Lobach IV; Tsai RM; Rabinovici GD; Miller BL; Boxer AL;
    Neurology; 2018 Jan; 90(4):e273-e281. PubMed ID: 29282336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsy - Richardson syndrome.
    Homma T; Mochizuki Y; Hara M; Kamei S; Mizutani T; Takubo H; Isozaki E; Takahashi M; Komori T; Hao H
    Rev Neurol (Paris); 2020 May; 176(5):353-360. PubMed ID: 32247606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain.
    Narasimhan S; Guo JL; Changolkar L; Stieber A; McBride JD; Silva LV; He Z; Zhang B; Gathagan RJ; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Nov; 37(47):11406-11423. PubMed ID: 29054878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct phosphorylation profiles of tau in brains of patients with different tauopathies.
    Samimi N; Sharma G; Kimura T; Matsubara T; Huo A; Chiba K; Saito Y; Murayama S; Akatsu H; Hashizume Y; Hasegawa M; Farjam M; Shahpasand K; Ando K; Hisanaga SI
    Neurobiol Aging; 2021 Dec; 108():72-79. PubMed ID: 34536819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
    Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
    BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome.
    Tsuboi Y; Josephs KA; Boeve BF; Litvan I; Caselli RJ; Caviness JN; Uitti RJ; Bott AD; Dickson DW
    Mov Disord; 2005 Aug; 20(8):982-8. PubMed ID: 15834857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.
    Nuebling G; Hensler M; Paul S; Zwergal A; Crispin A; Lorenzl S
    J Neurol; 2016 Aug; 263(8):1565-74. PubMed ID: 27230855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.
    Piras A; Collin L; Grüninger F; Graff C; Rönnbäck A
    Acta Neuropathol Commun; 2016 Mar; 4():22. PubMed ID: 26936765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of serum uric acid as risk factor for tauopathies.
    Schirinzi T; Di Lazzaro G; Colona VL; Imbriani P; Alwardat M; Sancesario GM; Martorana A; Pisani A
    J Neural Transm (Vienna); 2017 Sep; 124(9):1105-1108. PubMed ID: 28620833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant.
    Ling H; de Silva R; Massey LA; Courtney R; Hondhamuni G; Bajaj N; Lowe J; Holton JL; Lees A; Revesz T
    Neuropathol Appl Neurobiol; 2014 Feb; 40(2):149-63. PubMed ID: 23432126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases.
    Nogami A; Yamazaki M; Saito Y; Hatsuta H; Sakiyama Y; Takao M; Kimura K; Murayama S
    J Nippon Med Sch; 2015; 82(6):266-73. PubMed ID: 26823029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate digital quantification of tau pathology in progressive supranuclear palsy.
    Pansuwan T; Quaegebeur A; Kaalund SS; Hidari E; Briggs M; Rowe JB; Rittman T
    Acta Neuropathol Commun; 2023 Nov; 11(1):178. PubMed ID: 37946288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tau pathology and motor dysfunction in mice by urinary exosomes from progressive supranuclear palsy patients.
    Li Q; Liu H; Zhu Q; Zhang R; Liang D; Zhang J; Jin R; Chen Y; Qin C; Teng J
    Brain Res Bull; 2024 Oct; 216():111046. PubMed ID: 39111605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Gentry EG; Henderson BW; Arrant AE; Gearing M; Feng Y; Riddle NC; Herskowitz JH
    J Neurosci; 2016 Jan; 36(4):1316-23. PubMed ID: 26818518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration.
    Schofield EC; Caine D; Kril JJ; Cordato NJ; Halliday GM
    Mov Disord; 2005 Jan; 20(1):34-9. PubMed ID: 15390131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropathology of variants of progressive supranuclear palsy.
    Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA
    Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.